BioFunding, UKUK

Successful placing of shares


London – The British pharmaceutical company Protherics plc has issued 58 715 544 new ordinary shares for Euro 54 million to finance the company’s growth. Only recently, Protherics had acquired the US firm Macromed Inc. in a Euro 20 million all-share deal. Furthermore, Chairman Stuart Wallis announced that he has signed two other agreements, which expand the company’s drug pipeline: Protherics in-licensed intellectual property from Glenveigh Pharmaceutical and paid Euro 2.8 million in stock. With the third deal, Protherics took over co-development rights for Acadesine from Advanced In Vitro Cell Technologies SL for an undisclosed sum. The drug is a potential cure for chronic B-cell lymphocatic leukaemia. Protherics has already two marketed products with CroFab (pit viper antivenom) and DigiFab, a digoxin antidote, which is sold in the US through an Altana subsidiary.



London - The not-for-profit UK Biobank, the most comprehensive health study in Britain, is now accessible to researchers from industry and academia. The resource, which contains some 1,000 pieces of health and lifestyle...



London – The British Wellcome Trust announced on 20 March that it will launch a £200m business to invest directly in healthcare and life sciences companies. The business, up to now running under its working title Project Sigma,...



Nanopore sequencer Oxford Nanopore Technologies, a UK firm that promises its third-generation technology could theoretically sequence a human genome in 15 minutes, impressed scientists with the first public presentation of its...



GlaxoSmithKline (GSK) is further strengthening its activity in the area of rare diseases. The London-based pharma giant has signed an early-stage deal to develop and commercialise treatments for lysosomal storage disorders...



London/Montreal - Angiochem will collaborate with British pharma trust GlaxoSmithKline (GSK) plc on treatments for lysosomal storage diseases (LSD). London-based GSK will pay $300m, including up to $31.5m in upfront cash and...



London - GlaxoSmithKline re-adjusts its €3.7bn R&D budget. Following a review, three of 38 R&D units will be cut and four new ones installed, the UK drug company said in a statement on 7 Februray. Furthermore, six of the...



London - AstraZeneca tries to shed some weight, anticipating a tough year ahead. 7,300 jobs will be gone soon, the Anglo-Swedish drug company said in a statement. Research and development operations will be cancelled in...



Newhouse – An example of Schumpeter's dictum of creative destruction can be witnessed in Scotland. A former research site of US-pharma company Merck will be reborn as a biotech science park. BioCity Scotland Ltd, a joint venture...

Displaying results 1 to 10 out of 396

1-10 Next >

© 2007-2015 BIOCOM

Product of the week



All Events

Current issue

All issues